Algert Global’s Axsome Therapeutics AXSM Stock Holding History

Algert Global’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$22.9M	Sell	135,460 -13,932	-9%	-$2.41M	0.34%	41
2025 Q4	$27.3M	Buy	149,392 +105,242	+238%	+$14.7M	0.43%	24
2025 Q3	$5.36M	Buy	44,150 +6,720	+18%	+$757K	0.09%	391
2025 Q2	$3.91M	Buy	37,430 +11,490	+44%	+$1.22M	0.08%	410
2025 Q1	$3.02M	Buy	+25,940	New	+$2.96M	0.07%	458
2024 Q3	–	Sell	-3,105	Closed	-$250K	–	1210
2024 Q2	$250K	Buy	+3,105	New	+$230K	0.01%	1196
2022 Q4	–	Sell	-6,040	Closed	-$270K	–	1138
2022 Q3	$270K	Buy	+6,040	New	+$302K	0.02%	970

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Algert Global's AXSM Position: Q1 2026 in Review

Algert Global reduced its Axsome Therapeutics (AXSM) stake by 9.3% in Q1 2026, selling an estimated $2.41M and leaving 135,460 shares worth $22.9M. The position accounts for 0.34% of the portfolio, ranked #41.

Algert Global first reported a position in AXSM in Q3 2022 and has held it in 7 quarters since. The position peaked at $27.3M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Algert Global held 135,460 shares of Axsome Therapeutics worth $22.9M as of Q1 2026.
Algert Global sold 13,932 Axsome Therapeutics shares in Q1 2026, an estimated $2.41M.
Axsome Therapeutics made up 0.34% of Algert Global's portfolio in Q1 2026, its #41 holding.
Algert Global first reported a position in Axsome Therapeutics in Q3 2022 and has held it in 7 quarters since.
Algert Global's Axsome Therapeutics position peaked at $27.3M in Q4 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Algert Global's 13F filing for Q1 2026, filed 14 May 2026.